Burzynski Research Institute (BZYR) Research & Development (2010 - 2025)
Burzynski Research Institute (BZYR) posted Research & Development of $260800.0 for Q4 2025, up 2.23% sequentially from $255117.0 in Q3 2025, and down 13.41% YoY from $301183.0 in Q4 2024.
Burzynski Research Institute (BZYR) Research & Development (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Research & Development for 16 years, with the latest figure at $260800.0 in Q4 2025.
- Quarterly Research & Development fell 13.41% year-over-year to $260800.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $1.0 million (down 2.61% YoY) and the FY2025 annual result came in at $1.0 million, up 20.92% from the prior year.
- Research & Development grew to $260800.0 in Q4 2025 per BZYR's latest filing, from $255117.0 in the prior quarter.
- Over five years, Research & Development peaked at $301183.0 in Q4 2024 and troughed at $127035.0 in Q1 2022.
- A 5-year average of $218939.6 and a median of $216090.5 in 2021 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development slumped 37.62% in 2022, then soared 45.33% in 2024.
- Over 5 years, Research & Development stood at $214112.0 in 2021, then dropped by 3.02% to $207651.0 in 2022, then gained by 5.02% to $218069.0 in 2023, then soared by 38.11% to $301183.0 in 2024, then decreased by 13.41% to $260800.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $260800.0, $255117.0, and $270272.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 260,800.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 260,800.00 |
| Aug 31, 2025 | 255,117.00 |
| May 31, 2025 | 270,272.00 |
| Feb 28, 2025 | 241,487.00 |
| Nov 30, 2024 | 301,183.00 |
| Aug 31, 2024 | 277,176.00 |
| May 31, 2024 | 226,088.00 |
| Feb 29, 2024 | 250,759.00 |
| Nov 30, 2023 | 218,069.00 |
| Aug 31, 2023 | 214,057.00 |
| May 31, 2023 | 182,114.00 |
| Feb 28, 2023 | 172,545.00 |
| Nov 30, 2022 | 207,651.00 |
| Aug 31, 2022 | 170,955.00 |
| May 31, 2022 | 167,354.00 |
| Feb 28, 2022 | 127,035.00 |
| Nov 30, 2021 | 214,112.00 |
| Aug 31, 2021 | 186,417.00 |
| May 31, 2021 | 231,946.00 |
| Feb 28, 2021 | 203,654.00 |